Shiraishi, Ikemura, Ueda, Kohno, Nakano, Tanaka, Nagatomo, Ikoma, Ono, Numasawa, Sakamoto, Nishikawa, Takei, Hakuno, Nakamaru, Ieda, Urashima, & Kohsaka (2026). Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial.. Heart (British Cardiac Society).
Shiraishi, Ikemura, Ueda, Kohno, Nakano, Tanaka, et al. Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial.. Heart (British Cardiac Society). 2026; PMID: 42009572
Shiraishi, Ikemura, Ueda, et al. Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial.[J]. Heart (British Cardiac Society). 2026.
@article{shiraishi2026,
author = {Shiraishi and Ikemura and Ueda and Kohno and Nakano and Tanaka and Nagatomo and Ikoma and Ono and Numasawa and Sakamoto and Nishikawa and Takei and Hakuno and Nakamaru and Ieda and Urashima and Kohsaka},
title = {Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial.},
journal = {Heart (British Cardiac Society)},
year = {2026},
note = {PMID: 42009572},
}
TY - JOUR AU - Shiraishi AU - Ikemura AU - Ueda AU - Kohno AU - Nakano AU - Tanaka AU - Nagatomo AU - Ikoma AU - Ono AU - Numasawa AU - Sakamoto AU - Nishikawa AU - Takei AU - Hakuno AU - Nakamaru AU - Ieda AU - Urashima AU - Kohsaka TI - Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial. T2 - Heart (British Cardiac Society) PY - 2026 AN - PMID:42009572 ER -
Introduction of guideline-directed medical therapy (GDMT) has transformed the care of heart failure (HF) with reduced ejection fraction, establishing four foundational drug classes. Yet, in clinical practice, many patients cannot initiate or maintain all four, and clinicians must pragmatically prioritise agents such as angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitor, whose comparative impacts are still explored. Moreover, the optimal loop diuretic to pair with modern GDMT, which enhances natriuresis, remains uncertain.